Pα+ Psychedelic Bulletin #164: Lykos Dominates News Cycle; EPIsoDE Trial Readout; EU Drug Report Discusses Psychedelics; DEA Should Improve RFRA Petition Process; Other News
- Lykos, Lykos, Lykos…
- A First Look at EPIsoDE Trial Results
- European Drug Report Briefly Discusses Psychedelics’ Potential Therapeutic Uses, Risks
- DEA Should Improve Religious Exemption Petition Process, Says U.S. Government Accountability Office
- Other Stories
Gosh, it’s been a busy few weeks! Our news cycle has been dominated by Lykos Therapeutics-related stories, from ICER’s report and panel meeting through to FDA’s Advisory Committee meeting and yesterday’s patent-related news.
Elsewhere in the psychedelics field, things have been a little quieter; especially for this author who was unable to attend the sixth edition of the Interdisciplinary Conference on Psychedelic Research (ICPR) in Haarlem.
Despite psychedelics companies taking a backseat on the news front as they let Lykos soak up the limelight—for better or worse—there are several headlines to share.
Let’s get you up to speed…
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks